harnessed a polymer‐based carrier system termed NIMOS for the co‐delivery of CyD1 siRNA and TNF‐α siRNA.[247] This dual siRNA delivery approach successfully reduced colonic TNF‐α and CyD1 levels, subsequently inhibiting specific pro‐inflammatory cytokines (IL‐1α and ‐β, interferon‐λ) and ultimately resulting in weight gain and alleviating symptoms in the colitis mouse model. Here, TNF is linked to colitis.